A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy

• Status: Not yet recruiting
• Trial end date: 2024-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in patients with hepatocellular carcinoma before and after proton therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Atomic Research Institute, Taiwan

Criteria

Inclusion Criteria:

• Diagnosed with hepatocellular carcinoma and scheduled to have the PBT.

• 20~80 years old

• Performance status: ECOG 0-1

• Child-Pugh class A

Exclusion Criteria:

• Massive or uncontrolled ascites

• Concurrent with other malignancy

• Under pregnancy or breastfeeding

• With distant metastasis

• Allergic to investigational drug(s) or similar drug(s)/ formulation(s);

• Known hypersensitivity to PRIMOVIST

• Acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m^2)

• General PET and MRI exclusion criteria

• Can't follow our follow-up schedule because of any reason